Delivery Order SPE2DP16D0008-0013
Award Date
9/21/16
Potential Completion Date
9/21/17
Potential Value
$149K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain, a component of the Department of Defense, to Genentech USA, Inc. The contract has a ceiling value of $353,101.26 and is for the delivery of oseltamivir phosphate, an antiviral medication. The contract was awarded under a larger federal supply schedule contract between Genentech and the Department of Veterans Affairs, valued at $4.9 billion, that enables the company to efficiently provide pharmaceuticals and...
This federal contract award, valued at $128,187.18, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The contract is a delivery order under a larger indefinite delivery vehicle with the DLA, valued at $27.9 million, to fulfill orders for medical supplies and critical pharmaceuticals supporting the Department of Defense's global health logistics network. The specific product being delivered under...
This federal contract award, SPE2DP16D0008|0021, was made by the Medical Supply Chain division of the Defense agency to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $101,188.26 firm-fixed-price delivery order is for the antiviral medication oseltamivir phosphate, with a performance period ending on September 22, 2017. The award is not associated with a set-aside program. Genentech USA, Inc. is a major supplier of pharmaceuticals and biologics to federal...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $85,938.87. The contract has a firm fixed price and does not utilize any set-aside designations. Genentech has several existing contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract has a firm fixed price, with a ceiling value of $88,842.60, and was awarded on September 8, 2017 with a completion date of September 10, 2018. The contract was not set aside for any special designation. Genentech holds several key contract vehicles with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a total ceiling value of $259,393.47. The contract is a firm-fixed price delivery order with a completion date of September 20, 2017. Genentech is the prime contractor, and no major subcontractors were identified. The contract is...
This is a delivery order under a Federal Supply Schedule contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $8,434,278.00 and a period of performance ending on September 20, 2017. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal agencies,...
This federal contract award, SPE2DP18D0011|SPE2DP18F6016, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The contract, valued at $115,959.93, is for the delivery of oseltamivir phosphate, a critical antiviral medication. The contract is a firm fixed-price Delivery Order, with a completion date of August 3, 2023. Genentech USA, Inc. has previously received several significant federal contract...
This is a delivery order (SPE2DP16D0008|0037) awarded by the Medical Supply Chain, a component of the Defense Logistics Agency, to Genentech USA, Inc. for the delivery of oseltamivir phosphate, an antiviral medication. The $105,688.08 firm fixed-price contract has a completion date of September 26, 2017. Genentech USA, Inc. is a foreign-owned, for-profit pharmaceutical manufacturer that provides a wide range of drugs and biologics to federal agencies through various contract vehicles,...